Nicotine abstinence syndrome precipitated by the competitive nicotinic antagonist dihydro-β-erythroidine

Pharmacology Biochemistry and Behavior

Volumn 60, Issue 3, 1998, Pages 609-613

  Malin, David H ^a,b   Lake, J Ronald ^a   Upchurch, Timothy P ^a   Shenoi, Merle ^a   Rajan, Nancy ^a   Schweinle, William E ^a  

^a UNIVERSITY OF HOUSTON CLEAR LAKE   (United States)

^b UH CL Box 237 ^*  (United States)

Author keywords

DH E; Nicotine dependence; Nicotine withdrawal; Nicotinic receptor antagonists; Rat; Scopolamine

Indexed keywords

DIHYDRO BETA ERYTHROIDINE; HEXAMETHONIUM; MECAMYLAMINE; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR BLOCKING AGENT; SCOPOLAMINE;

ANIMAL MODEL; ARTICLE; BRAIN THIRD VENTRICLE; CLINICAL ARTICLE; DEPENDENT PERSONALITY DISORDER; DOSE RESPONSE; DRUG EFFECT; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SMOKING CESSATION; SUBCUTANEOUS DRUG ADMINISTRATION; WITHDRAWAL SYNDROME;

ANIMALS; CHOLINERGIC AGENTS; DIHYDRO-BETA-ERYTHROIDINE; INJECTIONS, INTRAVENTRICULAR; MALE; MUSCARINIC ANTAGONISTS; NICOTINE; NICOTINIC ANTAGONISTS; RATS; RATS, SPRAGUE-DAWLEY; SCOPOLAMINE; SUBSTANCE WITHDRAWAL SYNDROME; SUBSTANCE-RELATED DISORDERS;

EID: 0031824511     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(98)00028-8     Document Type: Article

References (44)

1. Ali-Melkkilä, T.; Kanto, J.; Iisalo, E.: Pharmacokinetics and related pharmacodynamics of anticholinergic drugs. Acta Anaesthesiol. Scand. 37:633-642; 1993.
2. Ascher, P.; Large, W. A.; Rang, H. P.: Studies on the mechanism of action of acetylcholine antagonists on rat parasympathetic ganglion cells. J. Physiol. 295:139-170; 1979.
3. Bertrand, D.; Ballivet, M.; Rungger, D.: Activation and blocking of neuronal nicotinic acetylcholine receptor reconstituted in Xenopus oocytes. Proc. Natl. Acad. Sci. 87:1993-1997; 1990.
4. Brown, J. H.: Atropine, scopolamine, and related antimuscarinic drugs. In: Goodman Oilman, A.; Rail, T. W.; Nies, A. S.; Taylor, P., eds. The pharmacological basis of therapeutics, 8th ed. New York: Pergamon; 1990:150-165.
5. Bymaster, F. P.; Heath, I.; Hendrix, J. C.; Shannon, H. E.: Comparative behavioral and neurochemical activities of cholinergic antagonists in rats. J. Pharmacol. Exp. Ther. 267:16-24; 1993.
6. Cachelin, A. B.; Rust, G.: β-Subunits determine the sensitivity of rat neuronal nicotinic receptors. Eur. J. Physiol. 429:449-451; 1995.
7. Carboni, E.; Giua, C.; Di Chiara, G.: Changes in extracellular dopamine in the nucleus accumbens and in the prefrontal cortex of nicotine dependent rats are dissociated from physical abstinence syndrome. Soc. Neurosci. Abst. 22:164; 1996.
8. Chavez-Noriega, L. E.; Crona, J. H.; Washburn, M. S.; Urrutia, A.; Elliott, K. J.; Johnson, E. C.: Pharmacological characterization of recombinant human neuronal nicotinic acetylcholine receptors expressed in Xenopus oocytes. J. Pharmacol. Exp. Ther. 280:346-356; 1997.
9. Clarke, P. B. S.: The fall and rise of neuronal α-bungarotoxin binding proteins. Trends Pharmacol. Sci. 13:407-413; 1992.
10. Clarke, P. B. S.; Pert, C. B.; Pert, A.: Autoradiographic distribution of nicotinic receptors in rat brain. Brain Res. 323:390-395; 1984.
11. 3H]-dopamine release. Br. J. Pharmacol. 117:595-606; 1996.
12. Curzon, P.; Brioni, J. D.; Decker, M. W.: Effect in intraventricular injections of dihydro-beta-erythroidine (DHβE) on spatial memory in the rat. Brain Res. 714:185-191; 1996.
13. Damaj, M. I.; Martin, B. R.: Calcium agonists and antagonists of the dihydropyridine type: Effect on nicotine induced antinociception and hypomotility. Drug Alcohol Depend. 32:73-79; 1993.
14. Damaj, M. I.; Welch, S. P.; Martin, B. R.: In vivo pharmacological effects of dihydro-β-erythroidine, a nicotinic antagonist, in mice. Psychopharmacology (Berlin) 117:67-73; 1995.
15. Decker, M.W.; Brioni, J. D.; Bannon, A. W.; Arneric, S. P.: Diversity of neuronal nicotinic acetylcholine receptors: Lessons from behavior and implications for CNS therapeutics. Life Sci. 56:554-570; 1994.
16. Dohanich, G. P.; Ross, S. M.; Francis, T. J.; Fader, A. J.; Wee, B. E. F.; Brazier, M. M.; Menart, C. S.: Effects of a muscarinic antagonist on various components of female sexual behavior in the rat. Behav. Neurosci. 107:819-826; 1993.
17. Egan, T. M.; North, R. A.: Actions of acetylcholine and nicotine on rat locus coeruleus neurons in vitro. Neuroscience 19:565-571; 1986.
18. Elselé, J.-L.; Bertrand, S.; Galzl, J.-L.; Devillers-Thiéry, A.; Changeux, J.-P.; Bertrand, D.: Chimaeric nicotinic-serotonergic receptor combines distinct ligand binding and channel specificities. Nature 366:479-483; 1993.
19. Hadjiconstantinou, M.; Isola, R.; Wemlinger, T. A.; Tejwani, G. A.; Neff, N. H.: Nicotine alters met-enkephalin content and proenkephalin mRNA in the striatum of mice. Soc. Neurosci. Abstr. 22:164; 1996.
20. Harvey, S. C.; Leutje, C. W.: Determinates of competitive antagonist sensitivity on neuronal nicotinic receptor beta subunits. J. Neurosci. 16:3798-3806; 1996.
21. Harvey, S. C.; Maddox, F. N.; Leutje, C. W.: Multiple determinates of DHβE sensitivity on rat neuronal nicotinic receptor a subunits. J. Neurochem. 67:1953-1959; 1996.
22. Hildebrand, B. E.; Nomikos, G. G.; Bondjers, C.; Nisell, M.; Svensson, T. H.: Behavioral manifestations of the nicotine abstinence syndrome in the rat: Peripheral versus central mechanisms. Psychopharmacology (Berlin) 129:348-356; 1997.
23. Krnjevic, K.; Pumain, R.; Renaud, L.: The mechanism of excitation by acetylcholine in the cerebral cortex. J. Physiol. (Lond.) 215:447-465; 1971.
24. Levin, E. D.; Rose, J. E.; McGurk, S. R.; Butcher, L. L.: Characterization of the cognitive effects of combined muscarinic and nicotinic blockade. Behav. Neural Biol. 53:103-112; 1990.
25. 3H] (-)nicotine binding in rat cortex. Neuropharmacology 32:847-853; 1993.
26. Malin, D. H.; Lake, J. R.; Carter, V. A.; Cunningham, J. S.; Hebert, K. M.; Conrad, D. L.; Wilson, O. B.: The nicotinic antagonist mecamylamine precipitates nicotine abstinence syndrome in the rat. Psychopharmacology (Berlin) 115:180-184; 1994.
27. Malin, D. H.; Lake, J. R.; Newlin-Maultsby, P.; Roberts, L. K.; Lanier, J. G.; Carter, V. A.; Cunningham, J. S.; Wilson, O. B.: A rodent model of nicotine abstinence syndrome. Pharmacol. Biochem. Behav. 43:779-784; 1992.
28. Malin, D. H.; Lake, J. R.; Payne, M. C.; Short, P. E.; Carter, V. A.; Cunningham, J. S.; Wilson, O. B.: Nicotine alleviation of nicotine abstinence syndrome is naloxone-reversible. Pharmacol. Biochem. Behav. 53:81-85; 1996.
29. Malin, D. H.; Lake, J. R.; Schopen, C. K.; Kirk, J. W.; Sailer, E. E.; Lawless, B. A.; Upchurch, T. P.: Nicotine abstinence syndrome precipitated by central but not peripheral hexamethonium. Pharmacol. Biochem. Behav. 58:695-699; 1997.
30. Mulle, C.; Changeux, J.-P.: A novel type of nicotinic receptor in the rat central nervous system characterized by patch-clamp techniques. J. Neurosci. 10:169-175; 1990.
31. O'Dell, T. J.; Christensen, B. N.: Mecamylamine is a selective noncompetitive antagonist of NMDA- and ASP-induced currents in horizontal cells dissociated from the catfish retina. Neurosci. Lett. 94:93-98; 1988.
32. Quirarte, G. L.; Cruz-Morales, S. E.; Diaz del Guante, M. A.; Garcia, M.; Prado-Alcala, R. A.: Protective effect of under-reinforcement of passive avoidance against scopolamine-induced amnesia. Brain Res. Bull. 32:521-524; 1993.
33. 2-muscarinic receptor antagonist in aged memory-impaired rats. J. Neurosci. 15:1455-1462; 1995.
34. Riekkinen, P., Jr.; Koivisto, E.; Sirviö, J.; Riekkinen, P.: Joint modulation of neocortical electrical activity by nicotinic and muscarinic receptors. Brain Res. Bull. 27:137-139; 1991.
35. Riekkinen, P., Jr.; Koivisto, E.; Sirviö, J.; Riekkinen, P.: Joint modulation of neocortical electrical activity by nicotinic and muscarinic receptors. Brain Res. Bull. 27:137-139; 1991.
36. Riekkinen, P.; Riekkinen, M.; Sirviö, J.: Effects of nicotine on neocortical electrical activity in rats. J. Pharmacol. Exp. Ther. 267:776-784; 1993.
37. Riekkinen, P.; Riekkinen, M.; Sirviö, J.: Cholinergic drugs regulate passive avoidance performance via the amygdala. J. Pharmacol. Exp. Ther. 267:1484-1492; 1993.
38. Sethy, V. H.; Francis, J. W.: Regulation of brain acetylcholine concentration by muscarinic receptors. J. Pharmacol. Exp. Ther. 246:243-248; 1988.
39. Stolerman, I. P.; Chandler, C. J.; Garcha, H. S.; Newton, J. N.: Selective antagonism of behavioral effects of nicotine by dihydro-β-erythroidine in rats. Psychopharmacology (Berlin) 129:390-397; 1997.
40. Tien, X.; Wallace, L. J.: Trihexyphenidyl - Further evidence for muscarinic receptor subclassification. Biochem. Pharmacol. 34:588-590; 1985.
41. Williams, M.; Robinson, J.: Binding of the nicotinic cholinergic antagonist dihydro-β-erythroidine to rat brain tissue. J. Neurosci. 4:2906-2911; 1984.
42. Varanda, W. A.; Aracava, Y.; Sherby, S. N.; Van Meter, W. G.; Eldefrawi, M. E.; Albuquerque, E. X.: The ACh receptor of the neuromuscular junction recognizes mecamylamine as a noncompetitive antagonist. Mol. Pharmacol. 28:128-137; 1985.
43. 4, expressed in transfected eucaryotic cells. Mol. Brain Res. 28:101-109; 1995.
44. Yang, X.; Criswell, H. E.; Breese, G. R.: Nicotine-induced inhibition in medial septum involves activation of presynaptic nicotinic cholinergic receptors on γ-aminobutyric acid-containing neurons. J. Pharmacol. Exp. Ther. 276:482-489; 1996.